Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride)
- Region
- 🇪🇺 EU
- Active substance
- methylthioninium chloride
- Company
- Cosmo Technologies Ltd
- Status
- Authorised
- Therapeutic area
- Colorectal Neoplasms; Colonoscopy
- CHMP opinion
- Thu 25 Jun 2020
- EU approval
- Wed 19 Aug 2020
- Application
- EMEA/H/C/002776
- ATC
- V04CX
- Official record
- www.ema.europa.eu
Indication
Lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Methylthioninium chloride Proveblue Authorised · Provepharm SAS
Follow Lumeblue (previously Methylthioninium chloride Cosmo)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.